Business ❯ Pharmaceuticals ❯ Mergers and Acquisitions ❯ Novo Nordisk
Metsera cited an FTC warning about Novo’s bid structure, positioning Pfizer’s higher-upfront, more certain offer for a mid-November shareholder vote.
